Breakthrough SARS‐CoV‐2 infections in immune mediated disease patients undergoing B cell depleting therapy: A retrospective cohort analysis

OBJECTIVES: Patients with immune mediated inflammatory diseases (IMIDs) receiving B cell depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19 as well as the most likely to respond sub‐optimally to SARS‐CoV‐2 vaccines. However, little is known about the frequency or severity of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabrese, Cassandra M, Kirchner, Elizabeth, Husni, Elaine M, Moss, Brandon P, Fernandez, Anthony P, Jin, Yuxuan, Calabrese, Leonard H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Full Length
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349969/
https://www.ncbi.nlm.nih.gov/pubmed/35791921
http://dx.doi.org/10.1002/art.42287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349969/
https://www.ncbi.nlm.nih.gov/pubmed/35791921
http://dx.doi.org/10.1002/art.42287

Ejemplares similares